10/21/11

BG-12

Biogen MS trial data robust; shares jump | Reuters

"BG-12 may be a valuable treatment option for MS patients, combining strong efficacy, a favorable safety profile and oral administration," said Dr. Ralf Gold, a trial investigator and professor at St. Josef-Hospital/Ruhr-University in Bochum, Germany. "Preclinical research has shown that BG-12 has anti-inflammatory and neuroprotective effects."

No comments:

Post a Comment